The innovative, easy-to-administer oral option
Safely treat non-regenerative anemia in cats with chronic kidney disease
Varenzin™-CA1 (molidustat oral suspension) is the FIRST and ONLY FDA conditionally approved option for the treatment of CKD-related anemia, setting the new standard of care for cats suffering from the debilitating effects of this disease.
Features and benefits
- A first of its kind in veterinary medicine, Varenzin-CA1 stimulates a cat’s body to create its own erythropoietin (EPO)*
- Approved for convenient at-home treatment; no in-clinic injections needed
- No costly and inconvenient extra label use of erythropoietin stimulating agents (ESAs)
- Reasonable expectation of efficacy with minimal side effects1
*Versus administering with a human EPO product
1Varenzin Freedom of Information Summary, NADA 141-571.
